Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Genetic Technologies; Aushon Biosystems, Phadia

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies this week said that it has created a new North American molecular diagnostics division, which will be led by Lewis Stuart, formerly senior VP of commercial operations at CV Therapeutics. The division will be located in the Eastern US, said Genetic Technologies, and will be responsible for launching the firm's recently acquired BrevaGen test for non-hereditary breast cancer. The BrevaGen test and certain other assets were acquired earlier this year from the now-defunct Perlegen Sciences.


Aushon Biosystems this week said it has placed its 2470 Arrayer with Phadia, an Uppsala, Sweden-based blood diagnostics firm. Phadia's Multiplexing Diagnostics division will use the 2470 in its research efforts to characterize new allergens and to discover biomarker signatures that can be used in the molecular diagnosis of allergies and autoimmune diseases.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.